Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
NCT06077669 · Johns Hopkins University · PHASE4 · withdrawn · last registry update 2024-03-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study withdrawn in IRB by PI” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-06Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Contrave (NCT04499950)
- 2025-02-24Results posted on the registry: Boehringer Ingelheim, Elontril + BI 1358894 (NCT04899674)
- 2025-02-20Results posted on the registry: Medical University of South Carolina, a drug against SLC6A3 (NCT04907357)
- 2025-02-14Also stopped (withdrawn): University of California, Los Angeles, Medical weight loss (NCT05812183)
- 2025-02-05Results posted on the registry: University of Maryland, Baltimore, Bupropion (NCT03342027)
- 2025-01-24Phase 3 first posted: University of Chicago, Cystine (NCT06790342)
- 2025-01-09Results posted on the registry: University of Chicago, Methamphetamine + placebo oral tablet (NCT04642820)
- 2024-12-16Phase 3 first posted: Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) (NCT06736509)
- 2024-11-22Results posted on the registry: Pfizer, Voxelotor + Bupropion (NCT05981365)
- 2024-11-15Results posted on the registry: Oregon Health and Science University, Methamphetamine Hydrochloride Tablets + Placebo oral tablet (NCT03973489)
- 2024-10-24Also stopped (withdrawn): Stephen Ruedrich, Valbenazine Oral Capsule (NCT06107829)
- 2024-10-17Results posted on the registry: Yale University, Lisdexamfetamine Dimesylate (NCT03924193)
- 2024-10-09Phase 3 first posted: University of California, San Francisco, IM naltrexone (NCT06633900)
- 2024-10-04Results posted on the registry: InterveXion Therapeutics, LLC, IXT-m200 (NCT05034874)
- 2024-10-04Also stopped (terminated): InterveXion Therapeutics, LLC, IXT-m200 (NCT05034874)
- 2024-09-27Results posted on the registry: Pfizer, losartan + dextromethorphan (NCT03864042)
- 2024-09-23Also stopped (withdrawn): University of Nebraska, Methylphenidate + Placebo (NCT00792662)
- 2024-09-19Also stopped (terminated): The Cleveland Clinic, Phentermine / Topiramate Extended Release Oral Capsule + naltrexone/bupropion extended-release (NCT04531176)
- 2024-08-29Results posted on the registry: University of California, Irvine, Experimental: methylphenidate treatment (NCT00580814)
- 2024-08-29Results posted on the registry: University of Nebraska, Contrave + Contrave and Counseling (NCT03431831)
- 2024-08-15Results posted on the registry: Wuerzburg University Hospital, Methylphenidate, non-retard + Placebo (NCT01351272)
- 2024-07-22Results posted on the registry: The Cleveland Clinic, Phentermine / Topiramate Extended Release Oral Capsule + naltrexone/bupropion extended-release (NCT04531176)
- 2024-07-18Results posted on the registry: University of Florida, dl-Methylphenidate plus Cannabidiol + dl-Methylphenidate plus Cannabidiol Placebo solution (NCT04603391)
- 2024-07-15Also stopped (terminated): Weizmann Institute of Science, a drug against SLC6A3 (NCT04823364)
- 2024-06-07Results posted on the registry: Vastra Gotaland Region, Varenicline Tartrate 1 mg b.i.d + Bupropion Hydrochloride 150 mg b.i.d (NCT04167306)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision